Last reviewed · How we verify
NCT06218914
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Phase 1 trial testing NT-112: Autologous, engineered T Cells targeting KRAS G12D in Non-small Cell Lung Cancer in 108 participants. Currently enrolling.
30 August 2027
Quick facts
| Lead sponsor | AstraZeneca |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 108 |
| Start date | 22 March 2024 |
| Primary completion | 30 August 2027 |
| Estimated completion | 18 November 2043 |
| Sites | 18 locations across United States |
Drugs / interventions tested
- NT-112: Autologous, engineered T Cells targeting KRAS G12D — full drug profile →
- AZD0240: Autologous, engineered T Cells targeting KRAS G12D — full drug profile →
Conditions studied
- Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
- Colorectal Carcinoma — all drugs for Colorectal Carcinoma →
- Pancreatic Ductal Adenocarcinoma — all drugs for Pancreatic Ductal Adenocarcinoma →
- Endometrial Cancer — all drugs for Endometrial Cancer →
Sponsor
AstraZeneca — full company profile →
Who can join
18 and older, any sex, with Non-small Cell Lung Cancer or Colorectal Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Consensus, debate, and prospective on pancreatic cancer treatments.
Wang J, Yang J, Narang A, He J, et al · · 2024 · cited 56× · PMID 39390609 · DOI 10.1186/s13045-024-01613-x -
Current and Emerging Treatment Options for Pancreatic Cancer: A Comprehensive Review.
Hayat U, Croce PS, Saadeh A, Desai K, et al · · 2025 · cited 17× · PMID 40004658 · DOI 10.3390/jcm14041129 -
TCR-T cell therapy for solid tumors: challenges and emerging solutions.
He W, Cui K, Farooq MA, Huang N, et al · · 2025 · cited 10× · PMID 40129944 · DOI 10.3389/fphar.2025.1493346 -
Genetic Signature of Human Pancreatic Cancer and Personalized Targeting.
Reshkin SJ, Cardone RA, Koltai T. · · 2024 · cited 9× · PMID 38607041 · DOI 10.3390/cells13070602 -
Targeting the KRAS Oncogene for Patients with Metastatic Colorectal Cancer.
Miao R, Yu J, Kim RD. · · 2025 · cited 8× · PMID 40361439 · DOI 10.3390/cancers17091512 -
The complex journey of targeting RAS in oncology.
Wasiak K, Ciunowicz D, Kierasińska-Kałka A, Węgierska M, et al · · 2025 · cited 7× · PMID 40597785 · DOI 10.1186/s12885-025-14033-y -
Recent Anti-KRAS<sup>G12D</sup> Therapies: A "Possible Impossibility" for Pancreatic Ductal Adenocarcinoma.
Sobhani N, Pittacolo M, D'Angelo A, Marchegiani G. · · 2025 · cited 7× · PMID 40002297 · DOI 10.3390/cancers17040704 -
Updates in Immunotherapy for Pancreatic Cancer.
Chick RC, Pawlik TM. · · 2024 · cited 7× · PMID 39518557 · DOI 10.3390/jcm13216419
Verify or expand the search:
- PubMed search for NCT06218914
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
- NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
- NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
- NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
- NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting
Other AstraZeneca trials
Trials by the same sponsor.
- NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
- NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
- NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
- NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
- NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06218914 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
- Last refreshed: 9 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06218914.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing